21 results about "Human keratinocyte" patented technology

The invention discloses lactobacillus pentosus capable of converting various substances of dendrobium officinale to generate rich active small molecules and improving skin health, and belongs to the technical field of microorganisms. The lactobacillus pentosus (Lactobacillus pentosus) CCFM1482 obtained by screening can be used for producing various active substances by fermenting dendrobium officinale and regulating and controlling the synthesis of skin collagen factors, such as HSF cells (human skin fibroblasts), MDA (malondialdehyde), Nrf2 (nuclear factor E2 related factor 2) and HaCaT cells (human keratinocytes). Therefore, the lactobacillus pentosus CCFM1482 fermented dendrobium officinale kimura ex migo fermentation liquor has a huge application prospect in the preparation of products for preventing or treating the skin quality, and the dendrobium officinale kimura ex migo fermentation liquor can be used for preparing the products for preventing or treating the skin quality.

A skin care composition includes a plurality of agents that include at least one retinol derivative that may comprise, for example, hydroxypinacolone retinoate, and at least one bark extract that may comprise, for example, Eperua falcata bark extract, the plurality of agents providing reduced retinol associated inflammation as compared with a composition that includes the at least one retinol and lacks the at least one bark extract. The plurality of agents may also include hydroxy acid, for example, comprising lactic acid. The composition may confer one or a combination of increased skin cell proliferation, improved cellular migration, improved cellular differentiation, an anti-inflammatory retinol genetic signature as demonstrated by via bulk-RNA sequencing of human keratinocytes and restores epidermal disruption and reduce IL-1A and IL-23 inflammatory cytokines in human ex-vivo skin models of chronic inflammation.

A skin care composition includes a plurality of agents that include at least one retinol derivative and at least one bark extract, the plurality of agents providing reduced retinol associated inflammation as compared with a composition that includes the at least one retinol and lacks the at least one bark extract. The plurality of agents may include at least one retinol derivative comprising hydroxypinacolone retinoate and at least one bark extract which may include at least one bark extract comprising Eperua falcata bark extract. The plurality of agents may also include at least one hydroxy acid, for example, comprising lactic acid. The composition confers one or more of increased skin cell proliferation, improved cellular migration, improved cellular differentiation, or a combination thereof. Application the plurality of agents confers to skin cells and tissues an anti-inflammatory retinol genetic signature as demonstrated by via bulk-RNA sequencing of human keratinocytes and restores epidermal disruption and reduce IL-1A and IL-23 inflammatory cytokines in human ex-vivo skin models of chronic inflammation.

A method of immortalizing a human keratinocyte. Also provided are immortalized human keratinocytes, for example immortalized human keratinocytes that have been immortalized using the presently disclosed method. Further provided are organotypic cultures, co-cultures, assays and kits comprising one or more immortalized human keratinocytes. In one embodiment, the immortalized human keratinocyte is produced by sequentially deleting the p16 locus, using CRISPR-Cas9 based gene editing, followed by lentiviral-based introduction of the gene encoding human telomerase reverse transcriptase (hTERT).

This invention relates to the field of biomedical technology, specifically to the application of miR-133a-3p in the preparation of drugs for treating acute UVB skin damage. It reveals for the first time that restoring miR-133a-3p levels in epidermal cells and the human keratinocyte line HaCaT cells can alleviate acute UVB damage, providing an important therapeutic target for the treatment of UVB-induced acute skin damage.

The present invention relates to ex vivo methods for obtaining populations of human keratinocytes derived from human pluripotent stem cells (hPSCs).More particularly, the present invention relates to an automated method that combines in a sequential manner automated differentiation and amplification of a population of hPSC-derived keratinocytes.

The invention belongs to the technical field of gene engineering, and discloses recombinant human fibronectin as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin disclosed by the invention is as shown in SEQ ID NO. 1. The recombinant human fibronectin comprises three fragments which are derived from natural fibronectin and have high hydrophilicity and multiple integrin binding capacity, the fragments are expressed in escherichia coli, and the recombinant human fibronectin with high soluble expression quantity is obtained; the recombinant human fibronectin has high activity of promoting proliferation and migration of human keratinocytes, and has potential application prospects in the aspects of skin repair and wound healing.

The invention relates to a composition for treating eye diseases, which comprises human keratinocyte factor-2 and a protective agent, and the protective agent comprises: 1) one or more of 0.1%-2% (w / v) mannitol and 0.01%-0.05% (w / v) sodium hyaluronate; 2) 0.1%-2% (w / v) glycerol; 3) 0.1%-2% (w / v) of one or more of trehalose or 0.5% (w / v) of human serum albumin; and 4) 0.1%-2% (w / v) of one or more of lysine hydrochloride. The compatibility of an hKGF-2 stock solution and auxiliary materials is explored to obtain a better concentration range of a protective agent, a surfactant and a pH regulator in the composition, and on the basis of the obtained better concentration range of each pharmaceutic auxiliary material, the melting (denaturation) temperature and aggregation temperature of hKGF-2 protein in a solution system are explored to determine a better prescription, so that the pharmaceutical composition is suitable for clinical application. The hKGF-2 protein activity in the obtained prescription can be kept stable for a long time. In addition, compared with eye drops provided in the prior art, the hKGF-2 eye drops provided by the invention have a better effect in the aspect of xerophthalmia treatment.

This invention relates to the field of natural product pharmaceuticals, and more particularly to a spirobroussonin compound, its preparation method, and its application. The spirobroussonin C provided by this invention is isolated from the paper mulberry tree. This compound can inhibit the release of the inflammatory factor IL-13 from human keratinocytes induced by IL-4 / TNF-α, exhibiting activity superior to the clinical drug dexamethasone and without cytotoxicity. It can significantly alleviate ear dryness and excessive angiogenesis in MC903-induced atopic dermatitis mice, reduce ear swelling, epidermal thickening, and transepidermal water loss, alleviate the trend of weight loss, reduce mast cell infiltration, and inhibit the expression of serum IgE and Th2-type cytokines such as IL-13, IL-4, and TSLP in ear tissue. No glucocorticoid-like side effects such as skin atrophy or metabolic disorders were observed with Spirobroussonin C within the experimental dose range.

The invention provides an HPV (human papillomavirus) infected human epidermal keratinocyte model and a construction method and application thereof, and relates to the technical field of molecular biology, an HPV genome is integrated to a KRT5 site of genome DNA (deoxyribonucleic acid) of human epidermal keratinocytes to obtain the HPV infected human keratinocyte model, stable integration and expression of an HPV whole genome are successfully realized, and the HPV infected human keratinocyte model is obtained. The position effect caused by random insertion is avoided, and the genetic stability is ensured; the model has the synergistic expression function of HPV early and late genes, maintains the time sequence of virus gene expression, realizes HPV virus particle assembly, and simulates the complete life cycle of HPV. The technical problem that in the prior art, an infection model cannot simulate the complete life cycle of the HPV is solved.

This invention provides a stem cell preparation for skin repair and its application, belonging to the field of biomedical technology. The stem cell preparation is obtained by inducing stem cells in a composite culture medium containing sodium butyrate, L-carnosine, and quercetin, followed by short-term pulsed hypoxia treatment, ultrasonic disruption, deep freeze-thaw rehydration, and vacuum freeze-drying to obtain a lyophilized stem cell powder. Experimental results show that the stem cell preparation of this invention significantly promotes the proliferation of human skin fibroblasts and significantly promotes the migration of human keratinocytes. In a mouse full-thickness skin defect model, local application after reconstitution in PBS buffer containing 0.1% sodium hyaluronate (concentration ≥100 μg / mL) significantly accelerates wound closure. In summary, the preparation of this invention exhibits high activity, strong stability, and broad prospects for clinical translation.

The invention relates to the technical field of medicines, in particular to a self-assembled polypeptide nano-drug and application thereof. The assembled polypeptide nano drug is Nap-FFGHLQGDVRWRKLFS, and is characterized in that the assembled polypeptide nano drug is Nap- The self-assembled polypeptide nano-drug (NF-H) has higher binding affinity, and can effectively promote proliferation and migration of human keratinocytes. In addition, NF-H shows a remarkable effect of promoting light-damaged skin repair, and it is proved that the wound healing rate in a light-damaged mouse model is increased. The discoveries prove that the self-assembled polypeptide nano-drug simulating the FGF10 function has the potential in the aspect of treating the skin light injury.

This invention discloses the application of METTL14 inhibitors in the preparation of drugs for the prevention and treatment of skin injuries. This invention also reveals for the first time the downregulation of METTL14 in human keratinocytes (HaCaT cells), human skin fibroblasts (WS1 cells), and animal tissues by ultraviolet B (UVB) radiation. 6 The downregulation of METTL14 protein levels, mediated by the reduction of METTL14 expression, can treat skin damage, providing a new approach for developing interventional targets for drugs treating UV-induced skin radiation damage.

This invention discloses a method for predicting and validating the comprehensive skin toxicity of daily-use preservatives based on multi-pathway responses in keratinocyte-fibroblast co-culture, belonging to the technical field of daily chemical safety evaluation. This invention uses human keratinocytes (HaCaT) and human dermal fibroblasts (HSF) as dual targets, and assesses the mechanistic skin toxicity of preservatives through multiple endpoints including inflammation, barrier damage, cell senescence, and organelle damage, classifying them and guiding their formulation application. The method of this invention boasts high prediction accuracy, high sensitivity, high efficiency, and compliance with regulations. It overcomes the limitations of traditional methods that only focus on "cell viability," providing a panoramic analysis of the toxic action pathways of preservatives from three dimensions: gene expression (early signal), organelle damage (intermediate process), and population apoptosis (final outcome), avoiding false negatives caused by single endpoints and possessing broad application prospects.

The invention relates to the technical field of biological medicines, and particularly discloses a plant nano-vesicle composition or freeze-dried powder rich in plant nano-vesicles and application of the plant nano-vesicle composition or the freeze-dried powder rich in the plant nano-vesicles in preparation of cosmetics. The plant nano-vesicle composition is prepared from peony nano-vesicles, rhizoma polygonati nano-vesicles and daisy flower nano-vesicles, wherein the weight ratio of the peony nano vesicles to the rhizoma polygonati nano vesicles to the daisy flower nano vesicles is (1-20): (1-10): (1-5). Researches show that the plant nano-vesicle composition disclosed by the invention has an effect of promoting proliferation of human keratinocytes; therefore, the plant nano-vesicle composition has important application value when being used as an active ingredient for preparing cosmetics or drugs with the effect of promoting skin barrier repair.

The utility model relates to a reversible electroporation leading-in instrument with a variable red and blue light probe, which belongs to the technical field of essence absorption promoting beauty instruments and comprises a leading-in instrument main body, a power supply module is arranged in the leading-in instrument main body, and an input interface of the power supply module is positioned at the top of the leading-in instrument main body. And an output port is fixedly mounted at the top of the leading-in instrument main body. According to the reversible electroporation introduction instrument with the variable red and blue light probe, high-strength instantaneous electric pulses are applied to the skin surface through an output electrode at the top end of the replaceable probe, so that a reversible'temporary hydrophilic channel 'is generated on the skin to promote percutaneous penetration of drugs; the light emitter on the top of the replaceable probe emits variable red and blue light, the curative effect on II-III grade medium inflammatory acne is good, the promotion effect on human keratinocyte proliferation is achieved, and the problems that a common beauty instrument for promoting essence absorption is single in function, and the absorption efficiency of skin care products is low are solved.

ANTI-AGING SKINCARE COMPOSITION The invention relates to a skincare composition comprising a plurality of agents, each including at least one retinol derivative and at least one bark extract. The plurality of agents provides reduced retinol-associated inflammation compared to a composition that includes at least one retinol but lacks at least one bark extract. The plurality of agents may include at least one retinol derivative comprising hydroxypinacolone retinoate and at least one bark extract, which may include at least one bark extract comprising an extract of Eperua falcata bark. The plurality of agents may also include at least one hydroxy acid, for example, comprising lactic acid. The composition confers one or more of the following: increased skin cell proliferation, improved cell migration, improved cell differentiation, or a combination thereof.The application of multiple agents confers an anti-inflammatory retinol genetic signature to skin cells and tissues, as demonstrated by bulk RNA sequencing of human keratinocytes, and restores epidermal disruption and reduces the inflammatory cytokines IL-1A and IL-23 in ex vivo human skin models of chronic inflammation. Figure for abstract: none.

Biomarkers for post-traumatic stress disorder (PTSD) and biomarkers for fibromyalgia (FM), which is associated with a high rate of PTSD, have been identified by narrowing down biomarker genes from PTSD-related gene database on the basis of biological events related to disease conditions. In addition, Chinese herbal medicines that are potential therapeutic agents for PTSD have been identified through the examination and comparison of gene induction by Chinese herbal medicines and antipsychotics in human keratinocytes. The present method can provide: biomarkers applicable as indicators for the diagnosis and the development of therapeutic agents for PTSD and FM; effective Chinese herbal medicines for PTSD and FM; and a screening method for therapeutic agents for PTSD and FM.

Systems and methods for measuring cell senescence are provided herein.

The invention relates to the field of natural product medicines, in particular to a spirocyclic broussoninine compound as well as a preparation method and application thereof. The spiroring broussonin compound spirobroussonin C provided by the invention is separated from the broussonetia papyrifera. The compound can inhibit IL-4 / TNF-alpha induced human keratinocyte from releasing an inflammatory factor IL-13, the activity of the compound is superior to that of a clinical drug dexamethasone, the compound is free of cytotoxicity, ear dryness and excessive angiogenesis of MC903 induced atopic dermatitis mice can be remarkably relieved, ear swelling, epidermis thickening and percutaneous moisture loss of the mice are reduced, and the compound has a good application prospect. The traditional Chinese medicine composition can be used for relieving the weight loss trend, relieving mast cell infiltration and inhibiting expression of Th2 type cytokines such as serum IgE and ear tissue IL-13, IL-4 and TSLP. In the experimental dosage range of Spirobroussonin C, side effects such as skin atrophy and metabolic disorder similar to glucocorticoid are not observed.

The present invention relates to the technical field of model establishment, and provides a dimethylarsinous acid-induced malignantly transformed cell line of human keratinocytes and application thereof. In the present invention, human keratinocytes are persistently exposed to and incubated with a low dose of dimethylarsinous acid, to construct an inorganic arsenic metabolite dimethylarsinous acid (DMAIII)-induced malignantly transformed cell model of human keratinocytes. The malignantly transformed cell model of the present invention promotes the identification of carcinogenicity of arsenic methylated metabolites, and indicates that long-term exposure to low-dose arsenic metabolite dimethylarsinous acid (DMAIII) causes malignant transformation of skin cells, thus providing a new cell model basis and new research idea for the study of carcinogenic mechanism of arsenic.